IKT (Inhibikase Therapeutics) ROC %: -1,485.42% (As of Mar. 2026)

What is Inhibikase Therapeutics ROC %?

Inhibikase Therapeutics IKT -1.06% 36 ROC % is -1,485.42% as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Inhibikase Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -1,485.42%.

As of today (2026-06-25), Inhibikase Therapeutics's WACC % is 7.34%. Inhibikase Therapeutics's ROC % is -1134.61% (calculated using TTM income statement data). Inhibikase Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Inhibikase Therapeutics (NAS:IKT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Inhibikase Therapeutics's WACC % is 7.34%. Inhibikase Therapeutics's ROC % is -1134.61% (calculated using TTM income statement data). Inhibikase Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Inhibikase Therapeutics ROC % Related Terms

Inhibikase Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics ROC % Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-972.09

-1,970.54

-1,784.19

-2,442.46

-1,229.36

Inhibikase Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-2,224.45	-973.87	-1,023.03	-807.75	-1,485.42

36GF Score

Inhibikase Therapeutics Inc IKT

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Inhibikase Therapeutics ROC % Calculation

Inhibikase Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-53.348 * ( 1 - 0% )	/	( (1.259	+	7.42)	/ 2 )
=	-53.348	/	4.3395
=	-1,229.36 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	98.6	-	2.624	-	( 97.544	-	max(0, 3.734	-	98.451	+	97.544	))
=	1.259

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	181.205	-	1.977	-	( 178.764	-	max(0, 8.301	-	180.109	+	178.764	))
=	7.42

Inhibikase Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-72.86 * ( 1 - 0% )	/	( (7.42	+	2.39)	/ 2 )
=	-72.86	/	4.905
=	-1,485.42 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	181.205	-	1.977	-	( 178.764	-	max(0, 8.301	-	180.109	+	178.764	))
=	7.42

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	173.332	-	4.478	-	( 170.369	-	max(0, 5.712	-	172.176	+	170.369	))
=	2.39

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -1,485.42% mean?

Inhibikase Therapeutics (IKT) has a ROC % of -1,485.42% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Inhibikase Therapeutics and its competitors.

Is Inhibikase Therapeutics' ROC % too high?

Inhibikase Therapeutics' current ROC % is -1,485.42%. Overall, Inhibikase Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.

How does Inhibikase Therapeutics' ROC % compare to NKTX and CAMP?

Inhibikase Therapeutics' ROC % of -1,485.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current ROC % is -1,485.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Inhibikase Therapeutics stock overvalued right now?

Inhibikase Therapeutics (IKT) has a current ROC % of -1,485.42%. The current ROC % is -1,485.42%. Inhibikase Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current ROC % is -1,485.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies NKTX CAMP NERV WHWK VYGR YDES CRBU OBIO ARCT RNAC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801

Website https://www.inhibikase.com

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

36GF Score

Get the complete analysis for IKT

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87

Price

View IKT Analysis

See ROC % data for all stocks →